HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)-Reference-Cited by-同舟云学术

HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)

Published:2017-06 Issue: Volume:35 Page:138-138
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Abramson J.¹,Palomba M.L.²,Gordon L.³,Lunning M.⁴,Arnason J.⁵,Wang M.⁶,Forero-Torres A.⁷,Albertson T.⁸,Allen T.⁹,Sutherland C.¹⁰,Xie B.¹¹,Garcia J.⁸,Siddiqi T.¹²

Affiliation:

1. Hematology/Oncology; Massachusetts General Hospital Cancer Center; Boston USA

2. Hematologic Oncology; Memorial Sloan Kettering Cancer Center; New York USA

3. Hematology/Oncology; Northwestern University; Chicago USA

4. Oncology & Hematology; University of Nebraska Medical Center; Omaha USA

5. Hematology/Oncology; Beth Israel Deaconess Medical Center; Boston USA

6. Lymphoma & Myeloma; MD Anderson Cancer Center; Houston USA

7. Hematology & Oncology; University of Alabama at Birmingham; Birmingham USA

8. Clinical & Medical Affairs; Juno Therapeutics; Seattle USA

9. Clinical Operations; Juno Therapeutics; Seattle USA

10. Biomarkers and Translational Sciences; Juno Therapeutics; Seattle USA

11. Clinical Statistics; Juno Therapeutics; Seattle USA

12. Hematology & Hematopoietic Cell Transplantation; City of Hope National Medical Center; Duarte USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma;Advances in Clinical Medicine;2023

2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma;Cochrane Database of Systematic Reviews;2021-09-13

3. PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report;Frontiers in Immunology;2021-05-25

4. Identification of NY-ESO-1157–165 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy;Frontiers in Immunology;2021-03-23

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma;Journal for ImmunoTherapy of Cancer;2020-07